Neoadjuvant Tislelizumab Combined with Lenvatinib Plus Transcatheter Arterial Chemoembolization in Resectable Hepatocellular Carcinoma with High-Risk of Recurrence: A Prospective, Single-Arm, Phase II Trial.
Journal of Clinical Oncology（2024）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined